Comparison between body composition parameters and response to neoadjuvant chemotherapy by using pre-treatment PET CT in locally advanced breast cancer.
ASP, Acylation-stimulating protein
Adipose tissue
BMI, Body mass index
Body composition parameter
Breast cancer
CT, Computed tomography
Computed tomography
DCIS, Ductal carcinoma in situ
ER, Estrogen receptor
HER-2, Human epidermal growth factor receptor-2
IHC, Immunohistochemistry
MP, Miller -Payne
MT, Muscle tissue
NAC, Neoadjuvant chemotheraphy
PAI-1, Plasminogen activator inhibitor-1
PET, CT Positron-emission tomography-computed tomography
PR, Progesterone receptor
SAT, Subcutaneous adipose tissue
VAT, Visceral adipose tissue
ypCR, Pathological complete response
Journal
European journal of radiology open
ISSN: 2352-0477
Titre abrégé: Eur J Radiol Open
Pays: England
ID NLM: 101650225
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
10
2020
accepted:
06
11
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
10
12
2020
Statut:
epublish
Résumé
To compare the adipose and muscle tissue areas in patients who responded differently to neoadjuvant chemotherapy. One hundred and eighty six patients diagnosed with breast cancer who underwent neoadjuvant chemotherapy between January 2015- October 2019 and were operated after the treatment were retrospectively included in the study. Pathological results were divided into five groups using the Miller-Payne grading systems. Grade 1 indicating no significant reduction in malignant cells; Grade 2: a minor loss of malignant cells (≤ 30 %); Grade 3: reduction in malignant cells between 30 % and 90 %; Grade 4: disappearance of malignant cells >90 %; Grade 5: no malignant cells identifiable. Pre-treatment PET CT scans were evaluated, and calculation of body composition parameters were performed on a single axial section passing through the L3 vertebrae. Spearman's correlation test was used to analyze the correlation between SAT, VAT, MT parameters and pathological responses. There was no strong correlation between the 5 groups separated according to neoadjuvant chemotherapy treatment response and tissue distributions. However, that there was a very low correlation found between superficial adipose tissue and pathological response (r=, 156). In conclusion, our results have provided a very low correlation between SAT and more than 30 % response. More research is required to evaluate the role of the body fat and muscle parameters in response to neoadjuvant chemotherapy in larger patient populations.
Identifiants
pubmed: 33294497
doi: 10.1016/j.ejro.2020.100286
pii: S2352-0477(20)30075-7
pmc: PMC7689395
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100286Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors report no declarations of interest.
Références
Int J Breast Cancer. 2011;2011:523276
pubmed: 22295228
Oncologist. 2012;17(10):1240-5
pubmed: 22903527
Support Care Cancer. 2018 Mar;26(3):861-868
pubmed: 28948392
Breast Cancer Res Treat. 2014 Jul;146(1):183-8
pubmed: 24842266
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
PLoS One. 2012;7(7):e41380
pubmed: 22848477
JAMA Oncol. 2015 Aug;1(5):611-21
pubmed: 26182172
Ann Palliat Med. 2019 Jan;8(1):86-101
pubmed: 30525762
J Surg Res. 2015 Oct;198(2):371-6
pubmed: 25959832
Cancer Med. 2016 Jan;5(1):41-8
pubmed: 26626021
J Endocrinol Invest. 2002 Nov;25(10):855-61
pubmed: 12508947
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Breast. 2003 Oct;12(5):320-7
pubmed: 14659147
J Clin Oncol. 2008 Sep 1;26(25):4072-7
pubmed: 18757321
Lancet. 2014 Aug 30;384(9945):755-65
pubmed: 25129328
Breast. 2014 Jun;23(3):264-72
pubmed: 24530096
J Clin Oncol. 1999 Feb;17(2):460-9
pubmed: 10080586
Breast Cancer Res Treat. 2015 Jun;151(3):569-76
pubmed: 25962694
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Int J Cancer. 2009 Feb 1;124(3):698-712
pubmed: 18988226
J Obes. 2013;2013:291546
pubmed: 24073332
Epidemiol Rev. 2014;36:114-36
pubmed: 24375928
Cancer Manag Res. 2019 Nov 12;11:9563-9569
pubmed: 32009814
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
J Natl Cancer Inst Monogr. 2011;2011(43):86-90
pubmed: 22043049
Breast Cancer Res Treat. 2015 Feb;150(1):127-39
pubmed: 25677740
J Clin Oncol. 2008 Feb 10;26(5):778-85
pubmed: 18258986
Am J Epidemiol. 2014 Jan 1;179(1):95-111
pubmed: 24107615
J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56
pubmed: 15181022